Importantly, menin-MLL inhibitors are currently being clinically tested for relapsed or refractory acute myeloid leukaemias treatment and therefore may soon be introduced in clinical practice for treatment of this disease, reducing time required for its approval for treatment of other cancer types. Here, MEN1 is linked to cancer.